Key facts
- Spiral Therapeutics’s last known valuation is $52.0M (Apr 2026).
- It has raised $51.2M across 3 recorded rounds; the latest was Early Stage VC ($27.1M) in Sep 2025.
- Notable investors include StartX (US), Catalio Capital Management, Inveready Asset Management, Wille Finance, Albert Armengol — 14 tracked in total.
- Spiral Therapeutics has filed 4 Form Ds with the SEC since 2018, most recently Apr 2026 ($27.1M sold to 34 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Spiral Therapeutics
Funding rounds
3 roundsAbout Spiral Therapeutics
Developer of drug therapies designed to treat inner ear disorders. The company offers therapies targeting acute and subacute hearing loss and balance conditions, enabling patients to access treatment options for the prevention and management of hearing loss.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2016
- Employees
- 10
- Website
- spiraltx.com/
- Ownership
- Privately Held (backing)
Spiral Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spiral Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spiral Therapeutics in its N-PORT filings yet. We sweep new filings monthly.